Mitral Regurgitation Clinical Trial
Official title:
SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation
Verified date | January 2024 |
Source | InnovHeart |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical treatment following Heart Team assessment.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | December 2024 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 years or older. 2. Severe functional mitral regurgitation (= Grade 3+). 3. NYHA functional Class = II. If Class IV, patient must be ambulatory. 4. Treatment and compliance with optimal guideline-directed medical therapy (GDMT) for heart failure for at least 30 days. 5. Not a suitable candidate for open mitral valve surgery due to high operative risk, as determined by the Heart Team. 6. Able to complete quality-of-life assessment (KCCQ). General Exclusion Criteria: 1. Excessive frailty or comorbid conditions that preclude the anticipated benefit of the valve replacement. 2. Life expectancy <1 yr due to noncardiac conditions. 3. Active endocarditis. 4. Active systemic infection. 5. Modified Rankin Scale =4 disability. 6. Hemodialysis/ chronic renal failure (eGFR < 35 mL/min/m2). 7. Pulmonary arterial hypertension (fixed PAS < 60mmHg). 8) COPD on home oxygen. 9) Refuses blood transfusions. 10) Documented bleeding or coagulation conditions (hypo- or hyper-coagulable states). 11) Severe connective tissue disease under chronic immunosuppressive or cortisone therapy. 12) Pregnant/ lactating. Females of childbearing age must be willing to take contraceptives. 13) Participating in other investigational studies likely to confound the results or affect the study. 14) Unable to consent. 15) Unable or unwilling to comply with study Follow-up. 16) Patients classified as "vulnerable patients". Cardiovascular Exclusion Criteria: 1. Myocardial infarction during prior 30 days. 2. Stroke or TIA during prior 30 days. 3. Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed). 4. Prior mitral valve treatment (e.g. valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment. 5. Prior surgical mechanical valve AVR. 6. Prior TAVI. 7. Need for any cardiovascular surgery or intervention (other than for MV disease) within 30 days. 8. CRT or ICD implanted in previous 30 days. 9. Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or IABP/mechanical circulatory support. 10. CABG or PCI within previous 30 days. 11. Adequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure. No need for revascularization. 12. Prior or planned heart transplantation (UNOS status 1). 13. Physical evidence of right-sided congestive heart failure: 1. Patients with ascites. 2. Patients with anasarca (generalized edema / hydropsy). Procedural Exclusion Criteria: 14. Chest condition that prevents transapical access. 15. Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy). 16. Documented hypersensitivity to nickel or titanium. Cardiac Exclusion Criteria (evaluated by Core Labs): 1. Left ventricular EF = 30% by imaging. 2. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass. 3. Extensive mitral flail leaflets. 4. Left ventricular thrombus, mass, or vegetation. 5. Left ventricular end-diastolic diameter > 7.5 cm. 6. Severe right ventricular dysfunction. 7. Significant intracardiac shunt. 8. Anatomic ineligibility for SATURN valve as determined by the Screening Committee. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet University Hospital of Copenhagen | Copenhagen | |
Hungary | Heart And Vascular Center, Semmelweis University | Budapest | |
Lithuania | Vilnius University Hospital Santaros klinikos | Vilnius |
Lead Sponsor | Collaborator |
---|---|
InnovHeart |
Denmark, Hungary, Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from device-related or procedure-related major adverse events | Freedom from device-related or procedure-related major adverse events at 30 days (cardiac death, peri-procedural myocardial infarction, disabling stroke, renal failure requiring dialysis, life threatening bleeding). | 30 days | |
Primary | Reduction of mitral regurgitation | Reduction of mitral regurgitation to =1 at 30 days. | 30 days | |
Primary | Technical success | Technical success defined as alive patient at exit from procedure room, with all of the following:
Successful access, delivery and retrieval of the delivery systems. Development and correct positioning of the bioprosthesis. Freedom of additional emergency surgery or re-intervention related to the device or access procedure. |
Day 0 | |
Secondary | Freedom from device-related or procedure-related major adverse events | Freedom from device-related or procedure-related major adverse events throughout long- term follow-up.
Freedom from all-cause mortality |
30 days, 1 year, 2 years | |
Secondary | Freedom from all-cause mortality | Freedom from all-cause mortality | 30 days, 1 year, 2 years | |
Secondary | Patients success | Patients success | 30 days, 1 year, 2 years | |
Secondary | Device success | Device success | 30 days, 1 year, 2 years | |
Secondary | 6 Minute Hall Walk Test | Improvement from baseline in functional status by = 30 meters | 30 days, 1 year, 2 years | |
Secondary | KCCQ | Improvement from baseline in Quality of Life by = 10 points. | 30 days, 1 year, 2 years | |
Secondary | NYHA functional classification | Improvement from baseline by = 1 functional classification. | 30 days, 1 year, 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03278574 -
Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
|
N/A | |
Suspended |
NCT04960280 -
A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease
|
N/A | |
Recruiting |
NCT05021614 -
Valveclip® Transcatheter Mitral Valve Repair Study
|
N/A | |
Not yet recruiting |
NCT06167213 -
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Withdrawn |
NCT05040451 -
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
|
||
Withdrawn |
NCT03714412 -
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System
|
N/A | |
Recruiting |
NCT02592889 -
(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)
|
Phase 4 | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Completed |
NCT01841554 -
Cardioband With Transfemoral Delivery System
|
N/A | |
Not yet recruiting |
NCT01431222 -
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
|
Phase 4 | |
Not yet recruiting |
NCT03870516 -
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
|
N/A | |
Active, not recruiting |
NCT03230747 -
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
|
N/A | |
Enrolling by invitation |
NCT04031274 -
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
|
||
Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
Completed |
NCT05836480 -
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
|
||
Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
Recruiting |
NCT03975998 -
Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
|
||
Completed |
NCT01162083 -
Identifying an Ideal Cardiopulmonary Exercise Test Parameter
|
N/A | |
Suspended |
NCT00787293 -
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
|
Phase 2 |